---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018147"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:24:12.625076+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics enters license collaboration with Orbital; will consolidate it financially

## Summary
- Beam receives 75M shares of Orbital common stock; expects to consolidate Orbital under ASC 810.
- Cross-licenses for non-viral delivery and RNA design; exclusive fields for each party run three years.
- Beam's Giuseppe Ciaramella becomes Orbital interim CEO; other Beam executives take interim leadership roles.
- Three Beam directors (Burow, Evans, Maraganore) join Orbital board; ARCH Venture Partners holds Orbital stock.

## SEC filing metadata
- accession: 0000950170-22-018147
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/0000950170-22-018147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/beam-20220902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018147
- JSON: https://secwatch.observer/filing/0000950170-22-018147.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.